# OnCo record nct07159217 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07159217/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07159217", "NCT07159217" ;
  schema:name "Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer"@en ;
  schema:description "A phase 2 trial of disitamab vedotin, pembrolizumab, camrelizumab and other drugs in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07159217/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07159217> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "gallbladder-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/lenvatinib/> .